ResMarkerDB: a database of biomarkers of response to antibody therapy in breast and colorectal cancer

2019 edition

Judith PĂ©rez Granado

The development and clinical efficacy of therapeutic monoclonal antibodies for breast and colorectal cancer have contributed greatly to the improvement of patients’ outcomes by individualizing treatments according to their genetic background [1]. Responding patients, however, may become resistant to treatment in advanced stages. In other cases, patients may be resistant to treatment even though they are molecularly characterized to be responsive [2,3]. Although several databases characterize biomarkers of drug response, there is a need of resources that offer this information to the user in a harmonized manner.

Here, we present ResMarkerDB, a centralized repository that gathers information of biomarkers of response to FDA-approved therapeutic monoclonal antibodies in breast and colorectal cancer. ResMarkerDB was developed as a user-friendly web interface to show data in an organized way and facilitate exploration of current knowledge of these biomarkers. It integrates information from available public repositories and new data extracted and curated from the literature. All data are downloadable and were homogenized and standardized following community-based standards and available ontologies. ResMarkerDB allows prioritizing biomarker data and its response to therapy in a specific cancer type according to evidence supporting their association and potential clinical usefulness. The source of these associations is varied and includes publications and guidelines. Different levels of evidence are considered too, from pre-clinical to distinct clinical phases.

ResMarkerDB database currently features 266 biomarkers of diverse nature. These alterations are mapped to more than 100 distinct genes, and are involved in more than 500 biomarker-drug-tumor associations. ResMarkerDB aims to enhance translational research efforts in identifying existing and new actionable biomarkers of drug response in cancer. This new tool is available at

FUNDING: We received support from ISCIII-FEDER (PIE15/00008, CP10/00524, CPII16/00026), the EU H2020 Programme 2014-2020 under grant agreements no. 634143 (MedBioinformatics) and no. 676559 (Elixir-Excelerate). The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), PRB2-ISCIII and is supported by grant PT13/0001/0023, of the PE I+D+i 2013-2016, funded by ISCIII and FEDER. The DCEXS is a “Unidad de Excelencia María de Maeztu”, funded by the MINECO (ref: MDM-2014-0370).

[1] Chiavenna,S.M. et al. (2017) State of the art in anti-cancer mAbs. J. Biomed. Sci., 24, 15.
[2] Pruneri,G. et al. (2016) Biomarkers for the identification of recurrence in human epidermal growth factor receptor 2-positive breast cancer patients. Curr. Opin. Oncol., 28, 476–483.
[3] Bronte,G. et al. (2015) New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS? Oncotarget, 6.

Authors: Judith Pérez-Granado, Janet Piñero and Laura I. Furlong

Affiliation: IBI, GRIB, IMIM, UPF